BioProject,Run,EV_type,Source,disease,Disease_stage/treatment,Release_date,URL,EV isolated method,Project_Title,Project_Description
PRJNA911334,SRR22696370,sEV,Blood|Plasma,Positive antiphospholipid antibodies without thrombotic or obstretic complications,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696371,sEV,Blood|Plasma,Positive antiphospholipid antibodies without thrombotic or obstretic complications,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696372,sEV,Blood|Plasma,Positive antiphospholipid antibodies without thrombotic or obstretic complications,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696373,sEV,Blood|Plasma,Positive antiphospholipid antibodies without thrombotic or obstretic complications,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696374,sEV,Blood|Plasma,Positive antiphospholipid antibodies without thrombotic or obstretic complications,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696375,sEV,Blood|Plasma,Positive antiphospholipid antibodies without thrombotic or obstretic complications,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696376,sEV,Blood|Plasma,Positive antiphospholipid antibodies without thrombotic or obstretic complications,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696377,sEV,Blood|Plasma,Positive antiphospholipid antibodies without thrombotic or obstretic complications,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696378,sEV,Blood|Plasma,Primary antiphospholipid syndrome,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696379,sEV,Blood|Plasma,Primary antiphospholipid syndrome,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696380,sEV,Blood|Plasma,Primary antiphospholipid syndrome,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696381,sEV,Blood|Plasma,Primary antiphospholipid syndrome,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696382,sEV,Blood|Plasma,Primary antiphospholipid syndrome,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696383,sEV,Blood|Plasma,Primary antiphospholipid syndrome,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696384,sEV,Blood|Plasma,Primary antiphospholipid syndrome,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696385,sEV,Blood|Plasma,Primary antiphospholipid syndrome,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696386,sEV,Blood|Plasma,Healthy donor,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696387,sEV,Blood|Plasma,Healthy donor,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696388,sEV,Blood|Plasma,Healthy donor,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696389,sEV,Blood|Plasma,Healthy donor,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696390,sEV,Blood|Plasma,Healthy donor,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696391,sEV,Blood|Plasma,Healthy donor,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696392,sEV,Blood|Plasma,Healthy donor,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
PRJNA911334,SRR22696393,sEV,Blood|Plasma,Healthy donor,-,2023-07-18,https://pubmed.ncbi.nlm.nih.gov/37511365/,"sEVs were isolated from plasma using the ExoQuick Plasma prep and Exosome precipitation kit (System Biosciences SBI, Palo Alto, CA, USA) and characterised by NanoSight, Cryo-TEM, western blot and flow cytometry analysis (LSR Fortessa, BD Biosciences, Erembodegem, Belgium)",miRNAs screening in small extracellular vesicles (sEVs) from patients with primary antiphospholipid syndrome  (PAPS) (human),"To discover miRNAs implicate in PAPS pathogenesis, we isolated sEVs from plasma of PAPS patients, aPL patients (patients with positive antiphospholipid antibodies without thrombotic or obstretic complications) and control. Then, we extracted RNA total and we performed miRNA-sequencing.
Overall design: We then performed gene expression profiling analysis using data obtained from miRNA-seq of PAPS patients (N=8), control patients (N=8) and aPL patients (N=8). aPL patients are patients with antiphospholipid antibodies without associated thrombotic or obstretic complications.
Comparative gene expression profiling analysis of miRNA-seq data for APS, aPL and control groups."
